Palvella Therapeutics (PVLA) Operating Leases (2019 - 2026)

Palvella Therapeutics (PVLA) posted quarterly Operating Leases of $375000.0 for Q1 2026, down 12.99% quarter-over-quarter from $431000.0 in Q4 2025.

Palvella Therapeutics (PVLA) Operating Leases (2019 - 2026) Analysis & Trends

Palvella Therapeutics (PVLA) has reported Operating Leases for 7 consecutive years, with $375000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Operating Leases changed N/A year-over-year to $375000.0; the TTM figure through Mar 2026 stood at $375000.0 (changed N/A YoY), while the FY2025 annual figure was $431000.0, changed N/A from the prior year.
Operating Leases slipped to $375000.0 in Q1 2026 per PVLA's latest filing, from $431000.0 in the prior quarter.
Across five years, Operating Leases topped out at $14.4 million in Q1 2022 and bottomed at $375000.0 in Q1 2026.
Historically, Operating Leases has averaged $9.6 million across 4 years, with a median of $12.2 million in 2022.
Annual changes were most pronounced in 2022 — Operating Leases fell 15.42% — and 2023, when it retreated 10.05%.
Palvella Therapeutics' Operating Leases stood at $12.2 million in 2022, then dropped by 2.66% to $11.9 million in 2023, then tumbled by 96.38% to $431000.0 in 2025, then dropped by 12.99% to $375000.0 in 2026.
Business Quant data shows PVLA's Operating Leases at $375000.0 in Q1 2026, $431000.0 in Q4 2025, and $11.9 million in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Palvella Therapeutics	2.25 Bn	1.93 Bn	-

Download Data